Walleye Trading LLC Intellia Therapeutics, Inc. Transaction History

Walleye Trading LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $130,810 - $177,855	6,534 New	6,534 $146,000
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $207,096 - $289,184	-8,942 Reduced 42.3%	12,198 $371,000
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $668,446 - $967,789	21,140 New	21,140 $668,000
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $1.63 Million - $2.18 Million	-12,349 Reduced 38.91%	19,391 $2.6 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $1.59 Million - $4.23 Million	26,132 Added 465.98%	31,740 $5.14 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $261,276 - $469,277	5,608 New	5,608 $450,000
Q1 2020 May 15, 2020	SELL	$9.44 - $15.58 $57,942 - $95,630	-6,138 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $105,426 - $178,608	-10,108 Reduced 62.22%	6,138 $90,000
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $177,627 - $423,092	15,595 Added 2395.55%	16,246 $222,000
Q1 2018 May 15, 2018	SELL	$19.43 - $34.95 $24,268 - $43,652	-1,249 Reduced 65.74%	651 $14,000
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $33,041 - $59,128	1,900	1,900 $37,000

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $929M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.